US Congress Senate Bill 977 (Prior Session Legislation)

---

Spectrum: Partisan Bill (Republican 2-0)
Status: Introduced on April 1 2019 - 25% progression, died in committee
Action: 2019-04-01 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]

Establishes several requirements relating to the prices of prescription drugs. For example, state Medicaid drug-use review programs must require pharmacists to disclose an individual's out-of-pocket cost for a prescription drug, and the price without health insurance, at the point-of-sale. Additionally, health insurers must publish the co-payment amount for each covered prescription drug prior to the annual open-enrollment period. The bill also temporarily prohibits the retail list price of drugs and biologics from exceeding the lowest retail list price among Canada, France, the United Kingdom, Japan, or Germany.

Transparent Drug Pricing Act of 2019

Sen. Rick Scott [R-FL]

Sen. Josh Hawley [R-MO]

Date	Chamber	Action
2019-04-01	Senate	Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/senate-bill/977/all-info
Text	https://www.congress.gov/116/bills/s977/BILLS-116s977is.pdf